AMENDMENTS TO THE CLAIMS

Claim 1 (previously presented). A method for improving excretory potency of an urinary bladder, which comprises administering a therapeutically effective amount of a non-carbamate amine compound having an acetylcholinesterase-inhibiting action to a patient in need thereof.

Claim 2 (previously presented). The method according to claim 1, wherein said non-carbamate amine compound is a compound of the formula:

$$Ar - C - \begin{pmatrix} R' \\ I \\ C \\ I \\ R \end{pmatrix} - Y$$

wherein Ar is optionally condensed phenyl in which the phenyl moiety may be substituted by a substituent or substituents;

n is an integer of 1 to 10;

R and R' are hydrogen, halogen or an optionally substituted hydrocarbon group; Y is an optionally substituted amino or an optionally substituted nitrogen-

containing heterocyclic group;

or a salt thereof.

Claim 3 (previously presented). The method according to claim 1, wherein said non-carbamate amine compound has the formula:


wherein Ar is an optionally condensed phenyl in which the phenyl moiety may be substituted by a substituent or substituents;

n is an integer from 1 to 10;

R is hydrogen or an optionally substituted hydrocarbon group;

Y is an optionally substituted amino or an optionally substituted nitrogencontaining saturated heterocyclic group; or a salt thereof.

Claim 4 (previously presented). The method according to claim 3, wherein Ar is a group of the formula:



wherein ring A is an optionally substituted benzene ring; and rings C' and D' are each a 5- to 9-membered nitrogen-containing heterocycle which may further be substituted by oxo.

Claim 5 (previously presented). The method according to claim 3, wherein said ring A is a benzene ring which may be substituted by 1 or 2 substituents selected from (i) optionally halogenated lower alkyl, (ii) halogen, (iii) lower alkylenedioxy, (iv) nitro, (v) cyano, (vi) hydroxyl, (vii) optionally halogenated lower alkoxy, (viii) cycloalkyl, (ix) optionally halogenated lower alkylthio, (x) amino, (xi)mono-lower alkylamino, (xii) di-lower alkylamino, (xiii) 5- to 7-membered cyclic amino, (xiv) lower alkyl-carbonylamino, (xv) lower alkyl-sulfonylamino, (xvi) lower alkoxy-carbonyl, (xvii) carboxy, (xviii) lower alkyl-carbonyl, (xix) cycloalkyl-carbonyl, (xx) carbamoyl or thiocarbamoyl, (xxi) mono-lower alkyl-carbamoyl, (xxii) di-lower alkyl-carbamoyl, (xxiii) lower alkylsufonyl, (xxiv) cycloalkylsulfonyl, (xxv) phenyl, (xxvi) naphthyl, (xxvii) mono-phenyl-lower alkyl, (xxviii) di-phenyl-lower alkyl, (xxix) mono-phenyl-lower

alkyl-carbonyloxy, (xxx) di-phenyl-lower alkyl-carbonyloxy, (xxxi) phenoxy, (xxxii) monophenyl-lower alkyl-carbonyl, (xxxiii) di-phenyl-lower alkyl-carbonyl, (xxxiv) benzoyl, (xxxv)phenoxycarbonyl, (xxxvi) phenyl-lower alkyl-carbamoyl, (xxxvii) phenyl-lower alkyl-carbonylamino, (xxxix) phenyl-lower alkylamino, (xxxx) phenyl-lower alkylsulfonyl, (xxxxiii) phenyl-lower alkylsulfonyl, (xxxxiii) phenyl-lower alkylsulfonylamino, and (xxxxiv) phenylsulfonylamino;

٠,

wherein the phenyl, naphthyl, mono-phenyl-lower alkyl, di-phenyl-lower alkyl, mono-phenyl-lower alkyl-carbonyloxy, di-phenyl-lower alkyl-carbonyloxy, phenoxy, mono-phenyl-lower alkyl-carbonyl, di-phenyl-lower alkyl-carbonyl, phenyl-lower alkyl-carbonyl, phenyl-lower alkyl-carbonylamino, phenyl-lower alkylsulfonyl, phenyl-lower alkylsulfinyl, phenyl-lower alkylsulfonylamino and phenylsulfonylamino in (xxv) to (xxxxiv) may further be substituted by 1 to 4 substituents selected from lower alkyl, lower alkoxy, halogen, hydroxy, benzyloxy, amino, mono-lower alkylamino, di-lower alkylamino, nitro, lower alkyl-carbonyl and benzoyl; and

wherein rings C' and D' are each a 5- to 9-membered nitrogen containing heterocycle which may further be substituted by oxo and which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom.

Claim 6 (previously presented). The method according to claim 3, wherein n is 2.

Claim 7 (previously presented). The method according to claim 3, wherein R is:

(I) hydrogen or

(II) alkyl, alkenyl, alkynyl, cycloalkyl, bridged cyclic lower saturated hydrocarbon group, aryl, aralkyl, aryl-alkenyl, aryl- C_{2-12} alkynyl, cycloalkyl-alkyl or aryl-aryl- C_{1-10} alkyl which may be substituted by 1 to 5 substituents selected from (i) halogen, (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) optionally halogenated lower alkyl, (vii) optionally halogenated lower alkylthio, (ix) amino, (x) mono-lower alkylamino, (xi) dilower alkylamino, (xii) 5- to 7-membered cyclic amino and which may contain 1 to 3

heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (xiii) lower alkyl-carbonylamino, (xiv) lower alkyl-sulfonylamino, (xv) lower alkoxy-carbonyl, (xvi) carboxy, (xvii) lower alkyl-carbonyl, (xviii) carbamoyl or thiocarbamoyl, (xix) mono-lower alkyl-carbamoyl, (xx) di-lower alkyl-carbamoyl, (xxi) lower alkylsulfonyl, (xxii) lower alkoxy-carbonyl-lower alkyl, (xxiii) carboxy-lower alkyl, (xxiv) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino. (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, (xxv) C₆₋₁₄ aryl, (xxvi) C₇₋₁₆ aralkyl, (xxvii) ureido, 3methylureido, 3-ethylureido, 3-phenylureido, 3-(4-fluorophenyl)ureido, 3-(2methylphenyl)ureido, 3-(4-methoxyphenyl)ureido, 3-(2,4-difluorophenyl)ureido, 3-[3,5bis(trifluoromethyl)phenyl]ureido, 3-benzylureido, 3-(1-naphthyl)ureido, or 3-(2biphenylyl)ureido, (xxviii) thioureido, 3-methylthioureido, 3-ethylthioureido, 3phenylthioureido, 3-(4-fluorophenyl)thioureido, 3-(4-methylphenyl)thioureido, 3-(4methoxyphenyl)thioureido, 3-(2,4-dichlorophenyl)thioureido, 3-benzylthioureido, or 3-(1naphthyl)thioureido, (xxix) amidino, N¹-methylamidino, N¹-ethylamidino, N¹-phenylamidino, N¹,N¹-dimethylamidino, N¹,N²-dimethylamidino, N¹-methyl-N¹-ethylamidino, N¹,N¹diethylamidino, N¹-methyl-N¹-phenylamidino, or N¹,N¹-di(4-nitrophenyl)amidino, (xxx) guanidino, 3-methyl-guanidino, 3,3-dimethylguanidino, or 3,3-diethylguanidino, (xxxi) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methyl-piperidino)carbonyl, (4phenylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, (4-benzoylpiperidino)carbonyl, [4-(4fluorobenzoyl)piperidino]carbonyl, (4-methyl-piperazino)carbonyl, (4phenylpiperazino)carbonyl, [4-(4-nitrophenyl)piperazino]carbonyl, (4-benzylpiperazino)carbonyl, morpholinocarbonyl, or thiomorpholinocarbonyl, (xxxii) aminothiocarbonyl,

methylaminothiocarbonyl, or dimethylaminothiocarbonyl, (xxxii) aminosulfonyl, methylaminosulfonyl, or dimethylaminosulfonyl, (xxxiv) phenyl-sulfonylamino, (4-methylphenyl)sulfonylamino, (4-chloro-phenyl)sulfonylamino, (2,5-dichlorophenyl)sulfonylamino, (4-methoxyphenyl)sulfonylamino, (4-acetylaminophenyl)sulfonylamino, or (4-nitrophenyl)phenylsulfonylamino, (xxxv) sulfo, (xxxvi) sulfino, (xxxvii) sulfeno, (xxxviii) lower alkylsulfo, (xxxix) lower alkylsulfino, (xxxx) lower alkylsulfeno, (xxxxi) phosphono, and (xxxxii) di-lower alkoxyphosphoryl.

Claim 8 (previously presented). The method according to claim 3, wherein R is hydrogen.

Claim 9 (currently amended). The method according to claim 3, wherein Y is:

(A) a group of the formula:

$$-N < R^{5}$$

wherein R⁴ and R⁵ each is:

(I) hydrogen,

٠,

(II) alkyl, alkenyl, alkynyl, cycloalkyl, bridged cyclic lower saturated hydrocarbon group, aryl, aralkyl, aryl-alkenyl, aryl- C_{2-12} alkynyl, cycloalkyl-alkyl or aryl-aryl- C_{1-10} alkyl which may be substituted by 1 to 5 substituents selected from (i) halogen, (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) optionally halogenated lower alkyl, (vii) optionally halogenated lower alkylthio, (ix) amino, (x) mono-lower alkylamino, (xi) dilower alkylamino, (xii) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (xiii) lower alkyl-carbonylamino, (xiv) lower alkyl-sulfonylamino, (xv) lower alkoxy-carbonyl, (xvii carboxy, (xvii) lower alkyl-carbonyl, (xviii) carbamoyl, thiocarbamoyl, (xix) mono-lower alkyl-carbamoyl, (xx) di-lower alkyl-carbamoyl, (xxi) lower alkylsulfonyl, (xxii) lower alkoxy-carbonyl, (xxii) lower alkyl-carbamoyl, (xxii) lower alkoxy-carbamoyl, (xxiii) lower alkoxy-carbamoyl, (xxiiii) lower alkoxy-carbamoyl, (xxiiiii) lower alkoxy-carbamoyl, (xxiiiiiiiiiiiiiiiiiiiiiiiiii

carbonyl-lower alkyl, (xxiii) carboxy-lower alkyl, (xxiv) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, (xxv) C₆₋₁₄ aryl, (xxvi) C₇₋₁₆ aralkyl, (xxvii) ureido, 3-methylureido, 3-ethylureido, 3-phenylureido, 3-(4-fluorophenyl)ureido, 3-(2-methylphenyl)ureido, 3-(4-methoxyphenyl)ureido, 3-(2,4difluorophenyl)ureido, 3-[3,5-bis(trifluoromethyl)phenyl]ureido, 3-benzylureido, 3-(1naphthyl)ureido, or 3-(2-biphenylyl)ureido, (xxviii) thioureido, 3-methylthioureido, 3ethylthioureido, 3-phenylthioureido, 3-(4-fluorophenyl)thioureido, 3-(4methylphenyl)thioureido, 3-(4-methoxyphenyl)thioureido, 3-(2,4-dichlorophenyl)thioureido, 3benzylthioureido, or 3-(1-naphthyl)thioureido, (xxix) amidino, N¹-methylamidino, N¹ethylamidino, N¹-phenylamidino, N¹,N¹-dimethylamidino, N¹,N²-dimethylamidino, N¹-methyl-N¹-ethylamidino, N¹,N¹-diethylamidino, N¹-methyl-N¹-phenylamidino, or N¹,N¹-di(4nitrophenyl)amidino, (xxx) guanidino, 3-methyl-guanidino, 3,3-dimethylguanidino, or 3,3diethylguanidino, (xxxi) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methylpiperidino)carbonyl, (4-phenylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, (4benzoylpiperidino)carbonyl, [4-(4-fluorobenzoyl)piperidino]carbonyl, (4methylpiperazino)carbonyl, (4-phenylpiperazino)carbonyl, [4-(4nitrophenyl)piperazino]carbonyl, (4-benzylpiperazino)carbonyl, morpholinocarbonyl, or thiomorpholinocarbonyl, (xxxii) aminothiocarbonyl, methylaminothiocarbonyl, or dimethylaminothiocarbonyl, (xxxiii) aminosulfonyl, methylaminosulfonyl, or dimethylaminosulfonyl, (xxxiv) phenylsulfonylamino, (4-methylphenyl)sulfonylamino, (4chlorophenyl)sulfonylamino, (2,5-dichlorophenyl)sulfonylamino, (4methoxyphenyl)sulfonylamino, (4-acetylaminophenyl)sulfonylamino, or (4-

alkylsulfo, (xxxix) lower alkylsulfino, (xxxx) lower alkylsulfeno, (xxxxi) phosphono, and (xxxxii) di-lower alkoxyphosphoryl; (III) acvl of the formula: $-(C=O)-R^2$, $-(C=O)-OR^2$, $-(C=O)-NR^2R^3$, $-SO_2-R^2$, $-SO-R^2$, -(C=S)-COR² or -(C=S)NR²R³ wherein R² and R³ each is [1] hydrogen, [2] alkyl, alkenyl, alkynyl, cycloalkyl, bridged cyclic lower saturated hydrocarbon group, aryl, aralkyl, aryl-alkenyl, aryl-C₂. ₁₂ alkynyl, cycloalkyl-alkyl or aryl-aryl-C₁₋₁₀ alkyl which may be substituted by 1 to 5 substituents selected from (i) halogen, (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) optionally halogenated lower alkyl, (vii) optionally halogenated lower alkoxy, (viii) optionally halogenated lower alkylthio, (ix) amino, (x) mono-lower alkylamino, (xi) di-lower alkylamino, (xii) 5- to 7membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (xiii) lower alkyl-carbonylamino, (xiv) lower alkyl-sulfonylamino, (xv) lower alkoxy-carbonyl, (xvi) carboxy, (xvii) lower alkylcarbonyl, (xviii) carbamoyl or thiocarbamoyl, (xix) mono-lower alkyl-carbamoyl, (xx) di-lower alkyl-carbamoyl, (xxi) lower alkylsulfonyl, (xxii) lower alkoxy-carbonyl-lower alkyl, (xxiii) carboxy-lower alkyl, (xxiv) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, (xxv) C₆₋₁₄ aryl, (xxvi) C₇₋₁₆ aralkyl, (xxvii) ureido, 3-methylureido, 3-ethylureido, 3-phenylureido, 3-(4-fluorophenyl)ureido, 3-(2methylphenyl)ureido, 3-(4-methoxyphenyl)ureido, 3-(2,4-difluorophenyl)ureido, 3-[3,5bis(trifluoromethyl)phenyl]ureido, 3-benzylureido, 3-(1-naphthyl)ureido, or 3-(2biphenylyl)ureido, (xxviii) thioureido, 3-methylthioureido, 3-ethylthioureido, 3phenylthioureido, 3-(4-fluorophenyl)thioureido, 3-(4-methylphenyl)thioureido, 3-(4-

nitrophenyl)phenylsulfonylamino, (xxxv) sulfo, (xxxvi) sulfino, (xxxvii) sulfeno, (xxxviii) lower

methoxyphenyl)thioureido, 3-(2,4-dichlorophenyl)thioureido, 3-benzylthioureido, or 3-(1naphthyl)thioureido, (xxix) amidino, N¹-methylamidino, N¹-ethylamidino, N¹-phenylamidino, N¹,N¹-dimethylamidino, N¹,N²-dimethylamidino, N¹-methyl-N¹-ethylamidino, N¹,N¹diethylamidino, N¹-methyl-N¹-phenylamidino, or N¹.N¹-di(4-nitrophenyl)amidino, (xxx) guanidino, 3-methylguanidino, 3,3-dimethylguanidino, or 3,3-diethylguanidino, (xxxi) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methyl-piperidino)carbonyl, (4phenylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, [4-(4fluorobenzovl)piperidinolcarbonyl, (4-methylpiperazino)carbonyl, (4phenylpiperazino)carbonyl, [4-(4-nitrophenyl)piperazino]carbonyl, (4benzylpiperazino)carbonyl, morpholinocarbonyl, or thiomorpholinocarbonyl, (xxxii) aminothiocarbonyl, methylaminothiocarbonyl, or dimethylaminothiocarbonyl, (xxxiii) aminosulfonyl, methylaminosulfonyl, or dimethylaminosulfonyl, (xxxiv) phenylsulfonylamino, (4-methylphenyl)sulfonylamino, (4-chlorophenyl)sulfonylamino, (2,5dichlorophenyl)sulfonylamino, (4-methoxyphenyl)sulfonylamino, (4acetylaminophenyl)sulfonylamino, or (4-nitrophenyl)phenylsulfonylamino, (xxxv) sulfo, (xxxvi) sulfino, (xxxvii) sulfeno, (xxxviii) lower alkylsulfo, (xxxix) lower alkylsulfino, (xxxx) lower alkylsulfeno, (xxxxi) phosphono, and (xxxxii) di-lower alkoxyphosphoryl, [3] 5- to 14membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, [4] R² and R³ are taken together with the adjacent nitrogen atom to form a 5- to 9-membered nitrogen-containing saturated heterocyclic group which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, wherein the heterocyclic group may be substituted by 1 to 5 substituents selected

from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl; or

(B) a 5- to 9-membered nitrogen-containing saturated heterocyclic group which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom,

wherein said heterocyclic group may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl,

wherein the nitrogen atom in said nitrogen-containing saturated heterocyclic group may be substituted by (I) alkyl, alkenyl, alkynyl, cycloalkyl, bridged cyclic lower saturated hydrocarbon group, aryl, aralkyl, aryl-alkenyl, aryl-C₂₋₁₂ alkynyl, cycloalkyl-alkyl or aryl-aryl-C₁₋₁₀ alkyl which may be substituted by 1 to 5 substituents selected from (i) halogen, (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) optionally halogenated lower alkyl, (vii) optionally halogenated lower alkylthio, (ix) amino, (x) mono-lower alkylamino, (xi) di-lower alkylamino, (xii) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (xiii) lower alkyl-carbonylamino, (xiv) lower alkylsulfonylamino, (xv) lower alkoxy-carbonyl, (xvii) carboxy, (xviii) lower alkyl-carbonyl,

(xviii) carbamoyl or thiocarbamoyl, (xix) mono-lower alkyl-carbamoyl, (xx) di-lower alkylcarbamoyl, (xxi) lower alkylsulfonyl, (xxii) lower alkoxy-carbonyl-lower alkyl, (xxiii) carboxylower alkyl, (xxiv) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkylcarbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, (xxv) C_{6-14} aryl, (xxvi) C_{7-16} aralkyl, (xxvii) ureido, 3-methylureido, 3-ethylureido, 3-phenylureido, 3-(4-fluorophenyl)ureido, 3-(2methylphenyl)ureido, 3-(4-methoxyphenyl)ureido, 3-(2,4-difluorophenyl)ureido, 3-[3,5bis(trifluoromethyl)phenyllureido, 3-benzylureido, 3-(1-naphthyl)ureido, or 3-(2biphenylyl)ureido, (xxviii) thioureido, 3-methylthioureido, 3-ethylthioureido, 3phenylthioureido, 3-(4-fluorophenyl)thioureido, 3-(4-methylphenyl)thioureido, 3-(4methoxyphenyl)thioureido, 3-(2,4-dichlorophenyl)thioureido, 3-benzylthioureido, or 3-(1naphthyl)thioureido, (xxix) amidino, N¹-methylamidino, N¹-ethylamidino, N¹-phenylamidino, N¹.N¹-dimethylamidino, N¹.N²-dimethylamidino, N¹-methyl-N¹-ethylamidino, N¹.N¹diethylamidino, N¹-methyl-N¹-phenylamidino, or N¹,N¹-di(4-nitrophenyl)amidino, (xxx) guanidino, 3-methylguanidino, 3,3-dimethylguanidino, or 3,3-diethylguanidino, (xxxi) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methyl-piperidino)carbonyl, (4phenylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, [4-(4fluorobenzoyl)piperidino|carbonyl, (4-methylpiperazino)carbonyl, (4phenylpiperazino)carbonyl, [4-(4-nitrophenyl)piperazino]carbonyl, (4benzylpiperazino)carbonyl, morpholinocarbonyl, or thiomorpholinocarbonyl, (xxxii) aminothiocarbonyl, methylaminothiocarbonyl, or dimethylaminothiocarbonyl, (xxxiii) aminosulfonyl, methylaminosulfonyl, or dimethylaminosulfonyl, (xxxiv) phenylsulfonylamino, (4-methylphenyl)sulfonylamino, (4-chlorophenyl)sulfonylamino, (2,5dichlorophenyl)sulfonylamino, (4-methoxyphenyl)sulfonylamino, (4-acetylaminophenyl)sulfonylamino, or (4-nitrophenyl)phenylsulfonylamino, (xxxv) sulfo, (xxxvi) sulfino, (xxxvii) sulfeno, (xxxviii) lower alkylsulfo, (xxxix) lower alkylsulfino, (xxxx) lower alkylsulfeno, (xxxxi) phosphono, and (xxxxii) di-lower alkoxyphosphoryl, (II) acyl of the formula: $-(C=O)-R^2$, $-(C=O)-OR^2$, $-(C=O)-NR^2R^3$, $-SO_2-R^2$, $-SO-R^2$, $-(C=S)-OR^2$ or -(C=S)NR²R³ wherein R² and R³ each is [1] hydrogen, or [2] alkyl, alkenyl, alkynyl, cycloalkyl, bridged cyclic lower saturated hydrocarbon group, aryl, aralkyl, aryl-alkenyl, aryl-C₂. ₁₂ alkynyl, cycloalkyl-alkyl or aryl-aryl-C₁₋₁₀ alkyl which may be substituted by 1 to 5 substituents selected from (i) halogen, (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) optionally halogenated lower alkyl, (vii) optionally halogenated lower alkoxy, (viii) optionally halogenated lower alkylthio, (ix) amino, (x) mono-lower alkylamino, (xi) di-lower alkylamino, (xii) 5- to 7membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (xiii) lower alkyl-carbonylamino, (xiv) lower alkylsulfonylamino, (xv) lower alkoxy-carbonyl, (xvi) carboxy, (xvii) lower alkylcarbonyl, (xviii) carbamoyl or thiocarbamoyl, (xix) mono-lower alkyl-carbamoyl, (xx) di-lower alkyl-carbamoyl, (xxi) lower alkylsulfonyl, (xxii) lower alkoxy-carbonyl-lower alkyl, (xxiii) carboxy-lower alkyl, (xxiv) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7-membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkyl-carbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkylcarbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl, (xxv) C_{6-14} aryl, (xxvi) C_{7-16} aralkyl, (xxvii) ureido, 3-methylureido, 3-ethylureido, 3-phenylureido, 3-(4-fluorophenyl)ureido, 3-(2methylphenyl)ureido, 3-(4-methoxyphenyl)ureido, 3-(2,4-difluorophenyl)ureido, 3-[3,5bis(trifluoromethyl)phenyl]ureido, 3-benzylureido, 3-(1-naphthyl)ureido, or 3-(2biphenylyl)ureido, (xxviii) thioureido, 3-methylthioureido, 3-ethylthioureido, 3-

phenylthioureido, 3-(4-fluorophenyl)thioureido, 3-(4-methylphenyl)thioureido, 3-(4methoxyphenyl)thioureido, 3-(2,4-dichlorophenyl)thioureido, 3-benzylthioureido, or 3-(1naphthyl)thioureido, (xxix) amidino, N¹-methylamidino, N¹-ethylamidino, N¹-phenylamidino, N¹,N¹-dimethylamidino, N¹,N²-dimethylamidino, N¹-methyl-N¹-ethylamidino, N¹,N¹diethylamidino, N¹-methyl-N¹-phenylamidino, or N¹,N¹-di(4-nitrophenyl)amidino, (xxx) guanidino, 3-methylguanidino, 3,3-dimethylguanidino, or 3,3-diethylguanidino, (xxxi) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methylpiperidino)carbonyl, (4phenylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, (4-benzylpiperidino)carbonyl, [4-(4fluorobenzoyl)piperidino]carbonyl, (4-methylpiperazino)carbonyl, (4phenylpiperazino)carbonyl, [4-(4-nitrophenyl)piperazino]carbonyl, (4benzylpiperazino)carbonyl, morpholinocarbonyl, or thiomorpholinocarbonyl, (xxxii) aminothiocarbonyl, methylaminothiocarbonyl, or dimethylaminothiocarbonyl, (xxxiii) aminosulfonyl, methylaminosulfonyl, or dimethylaminosulfonyl, (xxxiv) phenylsulfonylamino, (4-methylphenyl)sulfonylamino, (4-chlorophenyl)sulfonylamino, (2,5dichlorophenyl)sulfonylamino, (4-methoxyphenyl)sulfonylamino, (4acetylaminophenyl)sulfonylamino, or (4-nitrophenyl)phenylsulfonylamino, (xxxv) sulfo, (xxxvi) sulfino, (xxxvii) sulfeno, (xxxviii) lower alkylsulfo, (xxxix) lower alkylsulfino, (xxxx) lower alkylsulfeno, (xxxxi) phosphono, and (xxxxii) di-lower alkoxyphosphoryl, or (III) 5- to 14-membered heterocyclic group which contains 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur and which may be substituted by 1 to 5 substituents selected from (1) halogen, (2) nitro, (3) cyano, (4) oxo, (5) hydroxy, (6) lower alkyl, (7) lower alkoxy, (8) lower alkylthio, (9) amino, (10) mono-lower alkylamino, (11) di-lower alkylamino, (12) 5- to 7membered cyclic amino which may contain 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon atoms and one nitrogen atom, (13) lower alkyl-carbonylamino, (14) lower alkylsulfonylamino, (15) lower alkoxy-carbonyl, (16) carboxy, (17) lower alkylcarbonyl, (18) carbamoyl or thiocarbamoyl, (19) mono-lower alkyl-carbamoyl, (20) di-lower alkyl-carbamoyl, and (21) lower alkylsulfonyl.

Claim 10 (previously presented). The method according to claim 3, wherein Y is a

group of the formula:

$$N-R^6$$

wherein R⁶ is hydrogen, optionally substituted hydrocarbon group, acyl, or optionally substituted heterocyclic group.

Claim 11 (previously presented). The method according to claim 3, wherein Ar is a group of the formula:

and when Ar is phenyl, the phenyl may be substituted by substituent(s) selected from (1) halogen, (2) C₁₋₆ alkoxy, (3) amino, (4) mono- or di-C₁₋₆ alkylamino, (5) pyrrolidino, (6) piperidino, (7) piperazino, (8) N-methylpiperazino, (9) N-acetylpiperazino, (10) morpholino, (11) hexamethylenimino, (12) imidazolyl, and (13) C₁₋₆ alkyl which may be substituted by a carboxy optionally esterified by C₁₋₆ alkyl;

wherein when Ar is condensed phenyl, its heterocyclic portion may be substituted by substituent(s) selected from (1) C_{1-6} alkyl, (2) C_{7-16} aralkyl which may be substituted by substituent(s) selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy and nitro, (3) C_{1-6} alkyl-carbonyl, (4) C_{7-16} aralkyl-carbonyl, (5) C_{6-14} aryl-carbonyl, (6) C_{1-6} alkyl-carbonyl- C_{6-14} aryl and (8) pyridyl;

n is 2;

R is hydrogen; and

Y is a group of the formula:

$$-\sqrt{N-R^{\epsilon}}$$

wherein R^6 is (1) hydrogen, (2) C_{1-6} alkyl which may have a substituent or substituents selected from cyano, hydroxy, mono- or di- C_{1-6} alkylamino, pyridyl, and carboxy optionally esterified, (3) C_{7-16} aralkyl which may be substituted by substituent(s) selected from halogen, C_{1-6} alkyl, hydroxy,

 C_{1-6} alkoxy, nitro, amino, cyano, carbamoyl, C_{1-6} alkoxy optionally substituted by carboxy which may be esterified, carbamoyl optionally substituted by C_{1-6} alkyl or amino optionally substituted by formyl, and C_{1-3} alkylenedioxy, (4) C_{1-6} alkyl which may be substituted by carboxy optionally esterified, or (5) C_{1-6} alkyl-carbonyl optionally substituted by mono- or di- C_{1-6} alkylamino.

Claim 12 (previously presented). The method according to claim 3, wherein Ar is a group of the formula:

n is 2;

R is hydrogen; and

Y is a group of the formula:

$$-\sqrt{N-R^6}$$

wherein R^{6} is a benzyl which may be substituted by 1 or 2 substituents selected from halogen, C_{1-3} alkyl, C_{1-3} alkoxy, cyano, nitro and hydroxy.

Claim 13 (previously presented). The method according to claim 1, which comprises:

8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro4H-pyrrolo[3,2,1-ij]quinolin-4-one;

8-[3-[1-(phenylmethyl)-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one; and

8-[3-[1-[(2-hydroxyphenyl)methyl)-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one; or a salt thereof.

Claim 14 (withdrawn). The pharmaceutical composition according to claim 1, wherein the amine compound is 9-amino-1,2,3,4-tetrahydroacridine of the formula:

or a salt thereof.

Claim 15 (withdrawn). A method for the treatment of dysuria which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Atty. Docket No. 2001-1276 Serial No. 09/960,477 June 30, 2004

Claim 16 (withdrawn). A method for the treatment of difficulty of urination which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 17 (original). A pharmaceutical composition for improving excretory potency of the urinary bladder which comprises a combination of an α -blocker and an non-carbamate amine compound having an acetylcholinesterase-inhibiting action.

Claim 18 (cancelled).

Claim 19 (withdrawn). A method for improving the excretory potency of a urinary bladder which comprises administering a therapeutically effective amount of an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action to a patient in need thereof.

Claim 20 (previously presented). A pharmaceutical composition for improving excretory potency of an urinary bladder which comprises 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one having an acetylcholinesterase-inhibiting action or a salt thereof together with a pharmaceutically acceptable carrier.

Claim 21 (withdrawn). A method for the treatment of dysuria caused by prostatomegaly which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 22 (withdrawn). A method for the treatment of dysuria caused by hypotonic bladder which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 23 (withdrawn). A method for the treatment of dysuria caused by hypotonic bladder induced by prostatic hypertrophy, hypotonic bladder induced by diabetes mellitus, hypotonic bladder induced by diabetic neuropathy, idiopathic hypotonic bladder, age-associated hypotonic bladder, hypotonic bladder induced by multiple sclerosis, hypotonic bladder induced by Parkinson's disease, hypotonic bladder induced by spinal cord injury, postoperative hypotonic bladder or hypotonic bladder induced by brain block, which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 24 (withdrawn). A method for the treatment of dysuria caused by neurogenic bladder which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 25 (withdrawn). A method for the treatment of dysuria caused by neurogenic bladder induced by diabetes mellitus, neurogenic bladder induced by diabetic neuropathy, neurogenic bladder induced by multiple sclerosis, neurogenic bladder induced by Parkinson's disease, neurogenic bladder induced by spinal cord injury or neurogenic bladder induced by brain block which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need thereof.

Claim 26 (original). Crystals of 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof.

Claim 27 (original). The crystals of claim 26, wherein the melting point of said crystals is above 110°C.

Claim 28 (original). The crystals of claim 26, wherein the melting point of said crystals is about 113°C to about 118°.

Atty. Docket No. 2001-1276 Serial No. 09/960,477 June 30, 2004

Claim 29 (original). A pharmaceutical composition which comprises the crystals of claim 26 together with a pharmaceutically acceptable carrier.

Claim 30 (previously presented). An acetylcholinesterase inhibitor comprising the pharmaceutical composition according to claim 29.

Claim 31 (withdrawn). A method for improving the excretory potency of a urinary bladder which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 29 to a patient in need thereof.

Claim 32 (withdrawn). A method for the treatment of micturition disorders which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 29 to a patient in need thereof.

Claim 33 (withdrawn). A method for the treatment of dysuria disorders which comprises administering a therapeutically effective amount of the pharmaceutical composition according to claim 29 to a patient in need thereof.

Claim 34 (withdrawn). A pharmaceutical composition for improving the excretory potency of urinary bladder, which comprises crystals of 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and an α -blocker.

Claim 35 (new). A method for improving excretory potency of an urinary bladder, which comprises administering a therapeutically effective amount of a non-carbamate amine compound having an acetylcholinesterase-inhibiting action and no contraction activity for urethra muscle to a patient in need thereof.

Claim 36 (new). A method for improving excretory potency of an urinary bladder, which comprises administering a therapeutically effective amount of a non-carbamate amine compound having an acetylcholinesterase-inhibiting action to a patient in need thereof, wherein said non-carbamate amine compound is a compound of the formula:

$$Ar - C - \begin{pmatrix} R' \\ I \\ C \\ I \\ R \end{pmatrix} - Y$$

wherein Ar is a group of the formula:

Tagram is in the appropriate

wherein when Ar is condensed phenyl, its heterocyclic portion may be substituted by substituent(s) selected from (1) C_{1-6} alkyl, (2) C_{7-16} aralkyl which may be substituted by substituent(s) selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy and nitro, (3) C_{1-6} alkyl-carbonyl, (4) C_{7-16} aralkyl-carbonyl, (5) C_{6-14} aryl-carbonyl, (6) C_{1-6} alkyl-carbonyl- C_{6-14} aryl and (8) pyridyl;

n is an integer of 1 to 10;

R and R' are hydrogen, halogen or an optionally substituted hydrocarbon group;

Atty. Docket No. 2001-1276 Serial No. 09/960,477 June 30, 2004

Y is an optionally substituted amino or an optionally substituted nitrogencontaining heterocyclic group; or a salt thereof.